CredoScientia - Bibliothèque

Safety and Survival Outcomes of Liver Resection following Triple Combination Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma.

Triple combination conversion therapy, involving transcatheter arterial chemoembolization (TACE) or hepatic arterial infusion chemotherapy (HAIC) combined with tyrosine kinase inhibitors (TKIs) and im…

Thérapies de Conversion

Long, Y., Huang, J., Liao, J., Zhang, D., Huang, Z., He, X., & Zhang, L. (2023). Safety and Survival Outcomes of Liver Resection following Triple Combination Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma.. Cancers (Basel), 15(24). https://doi.org/10.3390/cancers15245878

17/12/2023 Lire →

From Conversion to Resection for Unresectable Hepatocellular Carcinoma: A Review of the Latest Strategies.

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in China, accounting for the majority of primary liver cancer cases. Liver resection is the preferred curative method for earl…

Thérapies de Conversion

Liang, C., He, Z., Tao, Q., Tang, X., Jiang, L., Tu, X., Liu, Z., Chen, H., Xie, F., & Zheng, Y. (2023). From Conversion to Resection for Unresectable Hepatocellular Carcinoma: A Review of the Latest Strategies.. J Clin Med, 12(24). https://doi.org/10.3390/jcm12247665

13/12/2023 Lire →

[The Usefulness of RFA as a Conversion Therapy after Molecular Targeted Therapy for Advanced Hepatocellular Carcinoma-A Case of Long-Term Survival with Multidisciplinary Treatment].

In this study, we report a case in which molecular-targeted agents have been shown to be effective in the treatment of unresectable hepatocellular carcinoma(HCC), which has enabled a radical treatment…

Thérapies de Conversion

Matsumoto, T., Hayashi, H., Adachi, Y., Kanemitsu, K., Tajiri, T., Yumoto, S., Ogawa, D., Shiraishi, Y., Takematsu, T., Tsukamoto, M., Miyata, T., Nakagawa, S., Mima, K., Nitta, H., & Baba, H. (2023). [The Usefulness of RFA as a Conversion Therapy after Molecular Targeted Therapy for Advanced Hepatocellular Carcinoma-A Case of Long-Term Survival with Multidisciplinary Treatment].. Gan To Kagaku Ryoho, 50(13), 1928-1930.

01/12/2023 Lire →

Sintilimab, bevacizumab biosimilar, and HAIC for unresectable hepatocellular carcinoma conversion therapy: a prospective, single-arm phase II trial.

We assessed the efficacy and safety of sintilimab [an anti-programmed death (PD-1)] plus bevacizumab biosimilar (IBI305), and hepatic arterial infusion chemotherapy (HAIC) in patients with unresectabl…

Thérapies de Conversion

Liu, D., Mu, H., Liu, C., Zhang, W., Cui, Y., Wu, Q., Zhu, X., Fang, F., Zhang, W., Xing, W., Li, Q., Song, T., Lu, W., & Li, H. (2023). Sintilimab, bevacizumab biosimilar, and HAIC for unresectable hepatocellular carcinoma conversion therapy: a prospective, single-arm phase II trial.. Neoplasma, 70(6), 811-818. https://doi.org/10.4149/neo_2023_230806N413

01/12/2023 Lire →

Current Therapeutic Strategies for Hepatocellular Carcinoma in Japan.

Thérapies de Conversion

Kudo, M. (2023). Current Therapeutic Strategies for Hepatocellular Carcinoma in Japan.. Liver Cancer, 12(6), 497-509. https://doi.org/10.1159/000534304

01/12/2023 Lire →

A randomized, controlled trial of prulifloxacin as conversion therapy after intravenous carbapenem in the treatment of acute pyelonephritis caused by third generation cephalosporin resistant pathogens: A pilot study.

The efficacy of converting to oral fluoroquinolones after initial intravenous antibiotics for the treatment of acute pyelonephritis (APN) caused by the third-generation cephalosporin resistant Enterob…

Thérapies de Conversion

So-Ngern, A., Jirajariyavej, S., Thuncharoon, H., Khunthupat, N., Chantarojanasiri, T., & Montakantikul, P. (2023). A randomized, controlled trial of prulifloxacin as conversion therapy after intravenous carbapenem in the treatment of acute pyelonephritis caused by third generation cephalosporin resistant pathogens: A pilot study.. Clin Transl Sci, 16(12), 2709-2718. https://doi.org/10.1111/cts.13665

01/12/2023 Lire →

Impact of Surgical Management for Relapse After Conversion Hepatectomy for Initially Unresectable Colorectal Liver Metastasis: A Retrospective Cohort Study.

BACKGROUND: For patients with initially unresectable colorectal liver metastasis (IU-CRLM) receiving conversion therapy, disease relapse after conversion hepatectomy is common. However, few studies ha…

Thérapies de Conversion

Chen, Y., Zhu, D., Chen, M., Xu, Y., Ye, Q., Wang, X., Xu, P., Feng, Q., Ji, M., Wei, Y., Fan, J., & Xu, J. (2023). Impact of Surgical Management for Relapse After Conversion Hepatectomy for Initially Unresectable Colorectal Liver Metastasis: A Retrospective Cohort Study.. Clin Colorectal Cancer, 22(4), 464-473.e5. https://doi.org/10.1016/j.clcc.2023.08.007

01/12/2023 Lire →

British mental healthcare responses to adult homosexuality and gender non-conforming children at the turn of the twenty-first century.

The roots of the recent controversy about how mental health professionals should respond to gender non-conforming children are traced. To make historical sense, this paper distinguishes between episte…

Thérapies de Conversion

Pilgrim, D. (2023). British mental healthcare responses to adult homosexuality and gender non-conforming children at the turn of the twenty-first century.. Hist Psychiatry, 34(4), 434-450. https://doi.org/10.1177/0957154X231181461

01/12/2023 Lire →

Perioperative safety, oncologic outcome, and risk factors of salvage liver resection for initially unresectable hepatocellular carcinoma converted by transarterial chemoembolization plus tyrosine kinase inhibitor and anti-PD-1 antibody: a retrospective mu

BACKGROUND: To assess the perioperative safety, oncological outcomes, and determinants influencing the oncological outcomes of salvage liver resection for initially unresectable hepatocellular carcino…

Thérapies de Conversion

Lin, K. Y., Lin, Z. W., Chen, Q. J., Luo, L. P., Zhang, J. X., Chen, J. H., Wang, K., Tai, S., Zhang, Z. B., Wang, S. F., Zhang, J. Y., You, W. Y., Wang, B., You, P. H., Lin, K. C., Yang, T., & Zeng, Y. Y. (2023). Perioperative safety, oncologic outcome, and risk factors of salvage liver resection for initially unresectable hepatocellular carcinoma converted by transarterial chemoembolization plus tyrosine kinase inhibitor and anti-PD-1 antibody: a retrospective mu. Hepatol Int, 17(6), 1477-1489. https://doi.org/10.1007/s12072-023-10561-6

01/12/2023 Lire →

Systematic sequential therapy for liver resection and autotransplantation: A case report and review of literature.

BACKGROUND: Perihilar cholangiocarcinoma (pCCA) is a highly malignant tumor arising from the biliary tree. Radical surgery is the only treatment offering a chance of long-term survival. However, limit…

Thérapies de Conversion

Hu, C. L., Han, X., Gao, Z. Z., Zhou, B., Tang, J. L., Pei, X. R., Lu, J. N., Xu, Q., Shen, X. P., Yan, S., & Ding, Y. (2023). Systematic sequential therapy for liver resection and autotransplantation: A case report and review of literature.. World J Gastrointest Surg, 15(11), 2663-2673. https://doi.org/10.4240/wjgs.v15.i11.2663

27/11/2023 Lire →

Deep radiomics-based fusion model for prediction of bevacizumab treatment response and outcome in patients with colorectal cancer liver metastases: a multicentre cohort study.

BACKGROUND: Accurate tumour response prediction to targeted therapy allows for personalised conversion therapy for patients with unresectable colorectal cancer liver metastases (CRLM). In this study, …

Thérapies de Conversion

Zhou, S., Sun, D., Mao, W., Liu, Y., Cen, W., Ye, L., Liang, F., Xu, J., Shi, H., Ji, Y., Wang, L., & Chang, W. (2023). Deep radiomics-based fusion model for prediction of bevacizumab treatment response and outcome in patients with colorectal cancer liver metastases: a multicentre cohort study.. EClinicalMedicine, 65, 102271. https://doi.org/10.1016/j.eclinm.2023.102271

01/11/2023 Lire →

Survival benefit and impact of adjuvant therapies following FOLFOX-HAIC-based conversion therapy with unresectable hepatocellular carcinoma: a retrospective cohort study.

BACKGROUND: Recently, the conversion therapies of FOLFOX-HAIC for patients with unresectable hepatocellular carcinoma (uHCC) have dramatically increased the tumor responses and conversion rate; thus, …

Thérapies de Conversion

Pan, Y., Yuan, Z., Wang, J., Ngai, S., Hu, Z., Sun, L., Yang, Z., Hu, D., Chen, M., Zhou, Z., & Zhang, Y. (2023). Survival benefit and impact of adjuvant therapies following FOLFOX-HAIC-based conversion therapy with unresectable hepatocellular carcinoma: a retrospective cohort study.. J Cancer Res Clin Oncol, 149(16), 14761-14774. https://doi.org/10.1007/s00432-023-05243-7

01/11/2023 Lire →